Description of service

SSI will formulate the candidate antigens with their cationic liposomal adjuvant systems CAF01 or CAF09b. Short-term stability testing of the CAF-adjuvanted vaccines and physicochemical characterisation of the vaccines will be carried out.


8-12 weeks per project approx.


Grith Krøyer Wood

0045 32683943

Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b


Services do NOT include

In vivo testing of formulation is NOT included.

Possible Output

Optimised vaccine formulation with T cell inducing adjuvant and vaccine characterisation data.

Sample Requirements - input of users

The user must provide vaccine antigen ready to formulate with adjuvant, either lyophilised or in stable aqueous solution including documentation of physico-chemical properties and analytical methods to detect, quantify and characterise the antigen.

Lead Scientist

Ida Svahn Rasmussen

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2021 European Vaccine Initiative. Designed by European Vaccine Initiative